Table 3.
Clinical, Pathological, and Array QC Findings
| Groups | Clinical findings |
Histopathological findings |
Hybridization quality |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Age (range) | Sex | Race | NS | % Glomeruli with FSGS | % Foot process effacement | % Globally sclerotic glomeruli | % Tubular atrophy/interstitial fibrosis | Age of FFPE tissue | Scale factor | % Present calls | |
| Histopathologic diagnosis | ||||||||||||
| Normal | 9 | 31.9 (7–67) | 5F/4 mol/L | 4B/1H/4W | 0 | 0 | 0 | 0 | 0 | 0.3–5 years | 10 ± 8 | 30 ± 7 |
| MCD | 7 | 41.4 (14–64) | 4F/3 mol/L | 3B/4W | 7 | 0 | 93 ± 4 | 4 ± 4 | 0 | 0.3–2 years | 11 ± 10 | 32 ± 9 |
| FSGS | 8 | 42.9 (5–74) | 3F/5 mol/L | 2B/1A/5W | 7 | 25 ± 15 | 92 ± 8 | 22 ± 22 | 26 ± 23 | 1–3 years | 12 ± 7 | 28 ± 6 |
| COLL | 6 | 38.7 (20–57) | 4F/2 mol/L | 5B/1H | 5 | 41 ± 32 | 86 ± 21 | 12 ± 10 | 33 ± 28 | 2–4 years | 12 ± 5 | 30 ± 8 |
| Combined groups | ||||||||||||
| Normal + MCD | 16 | 36.1 (7–67) | 9F/7 mol/L | 7B/1H/8W | 7 | 0 | 37 ± 47 | 2 ± 3 | 0 | 0.3–5 years | 10 ± 8 | 31 ± 8 |
| FSGS + COLL | 14 | 41.1 (5–74) | 7F/7 mol/L | 7B/1A/1H/5W | 12 | 32 ± 24 | 90 ± 14 | 18 ± 18 | 29 ± 25 | 1–4 years | 12 ± 6 | 28 ± 7 |
MCD, minimal change disease; FSGS, focal segmental glomerulosclerosis; COLL, collapsing variant of focal segmental glomerulosclerosis. A, Asian; B, black; H, Hispanic; W, White; NS, Nephrotic Syndrome; QC, quality control.